100 percent subcutaneous | | Reported weight data | 12.4 % (36 mg, 72 wk, ATTAIN-1) | 24.2 % (12 mg, 48 wk, Phase 2) | | Food restriction | None | Not applicable | | Status | FDA-approved (Foundayo, April 2026) | Research substance, not approved | The table illustrates that the higher weight values of retatrutide result from a broader receptor activation and the injection-driven complete entry of the active substance, while orforglipron has its strength in ease of administration and oral availability
The possibility of an infectious etiology of Alzheimer disease
Mild side effects might be reported by some people, such as nausea, stomach discomfort, and diarrhea, especially when the addition of L-Carnitine supplements is first done
Like in the United States and most countries worldwide, Mounjaro (tirzepatide) requires a valid prescription from a licensed doctor
Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis
These figures summarise how HCG is commonly described in research literature and supplier documentation